The success of your drug candidates rely on your speed to market and compelling data for adoption. Clinical trials require significant time, costs, and energy, but with the right partner, you can maximize the success of your clinical trials and derisk drug R&D.
With AMRA, you not only get access to our MRI data analysts, global research sites, and high-precision body composition analysis, you also get a team of subject matter experts that know exactly what you need to generate robust data and propel your R&D projects to the next stage—as smoothly and as quickly as possible.
Save time and resources by involving AMRA early to help design your clinical protocol to ensure regulatory clearance. AMRA offers pharmaceutical companies expert input on clinical trials for wide-ranging therapeutic areas to help you answer key questions surrounding clinical study design, such as:
Use our body composition biomarkers in new ways to deepen your insights into complex pathological disease processes. Our biomarkers are driven by our constantly growing body composition database and machine learning approach.
We continue to develop new biomarkers and are also developing composite scores for neuromuscular disorders. Contact us to see what biomarkers are currently available and being developed for your next study!
What does the MRI data mean and what does it contribute? These are common questions researchers need to answer to make the data meaningful and understandable to key stakeholders, R&D management, regulatory agencies, early adopters, and potential investors.
Fortunately, AMRA can quickly interpret body composition measurements for you.